Policy decision making and outcomes research in drug utilization

Journal of Public Health

Volumn 13, Issue 5, 2005, Pages 257-264

  Rychlik, R ^a,b,c   Wertheimer, A ^b   Rusche, H ^c   Augustin, M ^d   Nelles, S ^a   Bocking W ^e  

^a Institute of Empirical Health Economics   (Germany)

^b TEMPLE UNIVERSITY   (United States)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

^e Research Association Public Health Saxony EV   (Germany)

Author keywords

Drug utilization; Efficacy and effectiveness; Health policy; Outcomes research; Policy decision making

Indexed keywords

ARTICLE; DRUG UTILIZATION; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; UNITED STATES;

EID: 25444470994     PISSN: 09431853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10389-005-0123-0     Document Type: Article

References (22)

1. Abel U, Koch A (1997) The mythology of randomization. In: Abel U, Koch A (eds) Nonrandomized comparative clinical studies. Proceedings of the International Conference on Nonrandomized Comparative Clinical Studies, 10-11 April 1997, Heidelberg, Germany. Symposion Publishing, Düsseldorf
2. Breyer F, Zweifel P (1997) Gesundheitsökonomie, 2nd edn. Springer, Berlin Heidelberg New York, p 29
3. Camann MA (2001) Outcomes of care: the use of conceptual models to "see the forest and the trees" in planning outcomes studies. Top Health Inf Manage 22(2):10-14
4. CDER/CBER (Center for Drug Evaluation and Research/Center for Biological Evaluation and Research) (2004) Guidance documents. http://www.fda.gov/cder/ guidance/index.htm
5. Dannehl K (1997) Experimental study versus non-experimental study: the non-experimental (non-randomized) study as a methodological compromise. In: Abel U, Koch A (eds) Non-randomized comparative clinical studies. Proceedings of the International Conference on Nonrandomized Comparative Clinical Studies, 10-11 April 1997, Heidelberg, Germany. Symposion Publishing, Düsseldorf
6. Healey A, Mirandola M, Amaddeo F, Bonizzato P, Tansella M (2000) Using health production functions to evaluate treatment effectiveness: an application to a community mental health service. Health Econ 9(5):373-383
7. Hoppe JD (2005) Qualitätswettbewerb, Nutzenbewertung und Patientenbeteiligung. Garanten für die Zukunft des GKV-Systems oder Wegbereiter für eine Zweiklassen-Medizin? Gesundh Ökon Qual Manag 10(1) (in print)
8. King JT Jr, Ratcheson RA (1998) Cost and outcomes analysis. Neurosurg Clin N Am 9(3):629-640
9. Lee SJ, Earle CC, Weeks JC (2000) Outcomes research in oncology: history, conceptual framework, and trends in the literature. J Natl Cancer Inst 92(3): 195-204
10. Lorenz W, Koller M (2002) Empirically-based concepts of outcome and quality of life. In: Gimmler A, Lenk C, Aumüller G (eds) Health and quality of life. Philosophical, medical, and cultural aspects, 2nd edn. LIT Verlag, Münster, pp 123-136
11. Michaelis J (1997) Reference-controlled observational studies - a new tool for post marketing studies and for evaluation of preventive measures. In: Abel U, Koch A (eds) Nonrandomized comparative clinical studies. Proceedings of the International Conference on Nonrandomized Comparative Clinical Studies, 10-11 April 1997, Heidelberg, Germany. Symposion Publishing, Düsseldorf
12. National Institute for Clinical Excellence (2004) Guide to the methods of technology appraisal (reference N0515). http://www.nice.org.uk/pdf/TAP_Methods. pdf
13. National Multiple Sclerosis Society (2005) Tysabri Suspended From The Market. Bulletin 03-31-2005: http://www.nationalmssociety.org/Research- 2005Feb28.asp
14. Orlewska E, Mierzejewki P (2000) Polish guidelines for conducting pharmacoeconomic evaluations. Farmakoekonomika Suppl 1:3-11
15. Prendergast ML, Podus D (2000) Drug treatment effectiveness: an examination of conceptual and policy issues. Subst Use Misuse 35(12-14):1629-1657
16. Roberts TG, Chabner BA (2004) Beyond fast track for drug approvals. New Engl J Med 351(5):501-505
17. Rychlik R (2004) Health economical evaluation of drug utilization - an international review. Gesundh Ökon Qual Manag 9(3):177-185
18. Rychlik R, Rusche H, Augustin M (2004) Systematics of drug benefit evaluation. Gesundh Ökon Qual Manag 9(4):245-252
19. Schmacke N (2004) Bewertung des Nutzens von Arzneimitteln aus ärztlicher Sicht. Gesundheits- und Sozialpolitik 58(5-6):42-47
20. Tunis SR, Stryer DB, Clancy CM (2003) Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290(12):1624-1632
21. Weisz JR, Weiss B, Donenberg GR (1992) The lab versus the clinic: effects of child and adolescent psychotherapy. Am Psychol 47(12):1578-1585
22. Williams JI, Höher J, Lauterbach KW (1998) Health services research. In: Troidl H, McKneally MF, Mulder DS, Wechsler AS, McPeek B, Spitzer WO (eds) Surgical research - basic principles and clinical practice, 3rd edn. Springer, New York, pp 533-554